Hepatobiliary tumors, including hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, and metastatic liver cancer, have seen limited advancements in treatment options and patient outcomes in recent years. Radical surgical resection remains the most effective approach for early-stage hepatobiliary malignancies, but the subtle initial symptoms often lead to missed opportunities for surgery. Conventional adjuvant treatments like radiotherapy and chemotherapy show limited efficacy due to the low sensitivity of hepatobiliary malignancies. The absence of a standardized chemotherapy regimen for advanced cases further contributes to the poor prognosis associated with these tumors. The development of targeted drugs for hepatobiliary malignancies faces challenges despite the high frequency of gene mutations in these tumors. Therefore, identifying prognostic markers and investigating mechanisms influencing tumor progression and outcomes are crucial for the discovery of new targeted therapies and improving patient survival rates.
This Research Topic aims to investigate the molecular mechanisms and treatment approaches for hepatobiliary tumors. It will concentrate on recent advancements in molecular biology, genomics, and targeted therapy for hepatobiliary tumors with the goals of: (1) discovering novel molecular targets such as gene mutations, signaling pathways, and biomarkers for early detection and targeted therapy, (2) enhancing treatment outcomes by refining targeted therapies and immunotherapies to improve patient prognosis, and (3) enhancing prognosis and monitoring through the utilization of biomarkers and imaging technologies for real-time assessment of treatment response. Ultimately, this Research Topi seeks to enhance the diagnostic accuracy, prognosis evaluation, and treatment efficacy of hepatobiliary tumors.
Specific themes include (1) Genetic and Molecular Analysis: Identification of novel genetic mutations and molecular pathways in hepatobiliary tumors. The role of epigenetic modifications and noncoding RNAs in tumorigenesis. (2) Biomarkers: Discover and validate biomarkers for early detection, prognosis and monitoring treatment response. Developing liquid biopsy technology for real-time disease monitoring. (3) Targeted therapy: Progress in targeted therapy, including small molecule inhibitors and monoclonal antibodies. Mechanisms of resistance to targeted therapies and strategies to overcome them. (4) Immunotherapy: The efficacy of immune checkpoint inhibitors and other immunotherapy methods. Combination therapies involving immunotherapy and targeted drugs. (5) Clinical trials and translational research: Clinical trial results of new therapeutic drugs and combinations. Translational research links laboratory discoveries to clinical applications.
Manuscript types include original research articles, reviews, clinical trial reports, case studies, and perspective/opinions.
Keywords:
Hepatocellular carcinoma, Cholangiocarcinoma, Gallbladder cancer, Metastatic liver cancer, Biomarker, Targeted therapy, Prognosis
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Hepatobiliary tumors, including hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, and metastatic liver cancer, have seen limited advancements in treatment options and patient outcomes in recent years. Radical surgical resection remains the most effective approach for early-stage hepatobiliary malignancies, but the subtle initial symptoms often lead to missed opportunities for surgery. Conventional adjuvant treatments like radiotherapy and chemotherapy show limited efficacy due to the low sensitivity of hepatobiliary malignancies. The absence of a standardized chemotherapy regimen for advanced cases further contributes to the poor prognosis associated with these tumors. The development of targeted drugs for hepatobiliary malignancies faces challenges despite the high frequency of gene mutations in these tumors. Therefore, identifying prognostic markers and investigating mechanisms influencing tumor progression and outcomes are crucial for the discovery of new targeted therapies and improving patient survival rates.
This Research Topic aims to investigate the molecular mechanisms and treatment approaches for hepatobiliary tumors. It will concentrate on recent advancements in molecular biology, genomics, and targeted therapy for hepatobiliary tumors with the goals of: (1) discovering novel molecular targets such as gene mutations, signaling pathways, and biomarkers for early detection and targeted therapy, (2) enhancing treatment outcomes by refining targeted therapies and immunotherapies to improve patient prognosis, and (3) enhancing prognosis and monitoring through the utilization of biomarkers and imaging technologies for real-time assessment of treatment response. Ultimately, this Research Topi seeks to enhance the diagnostic accuracy, prognosis evaluation, and treatment efficacy of hepatobiliary tumors.
Specific themes include (1) Genetic and Molecular Analysis: Identification of novel genetic mutations and molecular pathways in hepatobiliary tumors. The role of epigenetic modifications and noncoding RNAs in tumorigenesis. (2) Biomarkers: Discover and validate biomarkers for early detection, prognosis and monitoring treatment response. Developing liquid biopsy technology for real-time disease monitoring. (3) Targeted therapy: Progress in targeted therapy, including small molecule inhibitors and monoclonal antibodies. Mechanisms of resistance to targeted therapies and strategies to overcome them. (4) Immunotherapy: The efficacy of immune checkpoint inhibitors and other immunotherapy methods. Combination therapies involving immunotherapy and targeted drugs. (5) Clinical trials and translational research: Clinical trial results of new therapeutic drugs and combinations. Translational research links laboratory discoveries to clinical applications.
Manuscript types include original research articles, reviews, clinical trial reports, case studies, and perspective/opinions.
Keywords:
Hepatocellular carcinoma, Cholangiocarcinoma, Gallbladder cancer, Metastatic liver cancer, Biomarker, Targeted therapy, Prognosis
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.